IP Library Granted Patent US 8,592,363
Granted Patent B2
US 8,592,363 · App. 13/190,356 · Granted Nov 26, 2013

ψεrack peptide composition and method for protection against tissue damage due to ischemia

Inventor: Daria Mochly-Rosen (Menlo Park, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,592,363
App. No.
13/190,356
Granted
Nov 26, 2013
Kind
B2
Abstract

A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.

Claims (8)

1. A composition comprising ψεRACK peptide crosslinked to a carrier peptide via a Cys-Cys disulfide bond, wherein the carrier peptide comprises a Tat-derived peptide or a polyarginine peptide, and wherein the ψεRACK peptide comprises the amino acid sequence selected from the group consisting of SEQ NOs:6-18.

2. The composition of claim 1 , wherein the carrier peptide comprises the Tat-derived peptide.

3. The composition of claim 2 , wherein the Tat-derived peptide consists of the amino acid sequence of SEQ ID NO:5.

4. A composition comprising a ψεRACK peptide crosslinked to a carrier peptide via a Cys-Cys bond, wherein the carrier peptide comprises the sequence of SEQ ID NO:5 and the ψεRACK peptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs:6-10.

5. A composition comprising a ψεRACK peptide crosslinked to a carrier peptide via a Cys-Cys bond, wherein the carrier peptide comprises the sequence of SEQ ID NO:5 and the ψεRACK peptide consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:6-10.

6. A method for reducing in vivo damage due to ischemia, hypoxia or reperfusion injury, comprising administering to a subject the peptide according to claim 1 , 2 , 3 , 4 or 5 .

7. The method according to claim 6 , wherein said administering comprises parenterally administering.

8. The method according to claim 7 , wherein said administering comprises intravenously administering.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 16, 2012
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027715/0601 →
Continuity (6)
Continuation 12467897 · May 18, 2009
Continuation 11449966 · Jun 9, 2006
Continuation 10807553 · Mar 22, 2004
Continuation 10007363 · Nov 9, 2001
Provisional Application 60247830 · Nov 10, 2000
Related Publication 20120190624A1 · Jul 26, 2012